Screener
Ironwood Pharmaceuticals IRWD Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:09 PM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-020489
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Proceeds from revolving credit facility | — | 150,000 |
| Costs associated with revolving credit facility | — | (2,246) |
| Repayments of revolving credit facility | — | (65,000) |
| Net cash provided by (used in) financing activities | 216 | (106,970) |
| Effect of exchange rate changes on cash and cash equivalents | (329) | (32) |
| Net increase (decrease) in cash and cash equivalents | 126,897 | (3,595) |
| Cash and cash equivalents, beginning of period | 88,559 | 92,154 |
| Cash and cash equivalents, end of period | $215,456 | $88,559 |
Item 16. Form 10-K Summary
FAQ
- What is Ironwood Pharmaceuticals's financing cash flow?
- Ironwood Pharmaceuticals (IRWD) reported financing cash flow of $122K in Q4 2025.
- How has Ironwood Pharmaceuticals's financing cash flow changed year-over-year?
- Ironwood Pharmaceuticals's financing cash flow increased by 100.8% year-over-year, from -$14.89M to $122K.
- What is the long-term trend for Ironwood Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Ironwood Pharmaceuticals's financing cash flow has grown at a -63.8% compound annual growth rate (CAGR), from -$4.55M to $216K.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Ironwood Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude